よむ、つかう、まなぶ。
参考資料３ WHO Statement on the antigen composition of COVID-19 vaccines (5 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/newpage_00104.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 研究開発及び生産・流通部会 季節性インフルエンザワクチンの製造株について検討する小委員会（第2回 5／29）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
。 Athough neutralizing antibody titres have Deen shown to be important correlates
Of protection from SARS-CoV-2 infection and of estimates of vaccine effectiveness,
there are multiple components of immune protection elicited by infection and/or
vaccination. Data on the immune responses following XBB or」N.1 descendent
lineage infection or XBB.1.5 vaccination are largely restricted to neutralizing
antibodies and data on other aspects of the immune response, including cellular
immunity, are limited.
。 Immunodgenicity data against currently circulating SARS-CoV-2 variants are not
available for all COVID-19 vaccines.
。 Estimates of rVE against recently circulating SARS-CoV-2 variants, including XBB or
JN.1 descendent lineages, are limited in terms of the number of studies,
geodraphic diversity, vaccine platforms evaluated, populations assessed, duration
of follow-up and comparative estimates for monovalent XBB.1.5 vaccines VersuS
other formulations delivered during the same time period.
Recommendations for COVID-19 vaccine antigen
comDpOosition
As of April 2024, nearly all circulating SARS-CoV-2 variants reported in publicly
available databases are 」N.1 derived variants. As Virus evolution IS exDected to
continue from」N.1, future formulations of COVID-19 vaccines should aim to induce
enhanced neutralizing antibody responses to 」N.1 and its descendent lineages. One
apDroach recommended by TAG-CO-VAC js the use of a monovalent 」N.1
lineage (GenBank: PP298019, GISAID: EPI_ISL_18872762) antigen in vaccines.
The continued use of the current monovalent XBB.1.5 formulation will offer protection
given the neutralizing antibody responses to early」N.1 descendent lineages, and the
evidence from early rVE studies against 」N.1. However, it is expected that the ability
for XBB.1.5 vaccination to protect against symptomatic disease may De less robust as
SARS-CoV-2 evolution continues from」N.1. Other formulations and/or platforms that
achieve roDbust neutralizing antibody responses adgainst currently circulatindg variants,
particularly 」N.1 descendent lineages, can also be considered.
In accordance with WHO SAGE policy, vaccination Drogrammes should continue to use
any Of the WHO emergency-use listed or Dredualified COVID-19 vaccines and
vaccination should not be delayed in anticipation of access to vaccines with an
Of protection from SARS-CoV-2 infection and of estimates of vaccine effectiveness,
there are multiple components of immune protection elicited by infection and/or
vaccination. Data on the immune responses following XBB or」N.1 descendent
lineage infection or XBB.1.5 vaccination are largely restricted to neutralizing
antibodies and data on other aspects of the immune response, including cellular
immunity, are limited.
。 Immunodgenicity data against currently circulating SARS-CoV-2 variants are not
available for all COVID-19 vaccines.
。 Estimates of rVE against recently circulating SARS-CoV-2 variants, including XBB or
JN.1 descendent lineages, are limited in terms of the number of studies,
geodraphic diversity, vaccine platforms evaluated, populations assessed, duration
of follow-up and comparative estimates for monovalent XBB.1.5 vaccines VersuS
other formulations delivered during the same time period.
Recommendations for COVID-19 vaccine antigen
comDpOosition
As of April 2024, nearly all circulating SARS-CoV-2 variants reported in publicly
available databases are 」N.1 derived variants. As Virus evolution IS exDected to
continue from」N.1, future formulations of COVID-19 vaccines should aim to induce
enhanced neutralizing antibody responses to 」N.1 and its descendent lineages. One
apDroach recommended by TAG-CO-VAC js the use of a monovalent 」N.1
lineage (GenBank: PP298019, GISAID: EPI_ISL_18872762) antigen in vaccines.
The continued use of the current monovalent XBB.1.5 formulation will offer protection
given the neutralizing antibody responses to early」N.1 descendent lineages, and the
evidence from early rVE studies against 」N.1. However, it is expected that the ability
for XBB.1.5 vaccination to protect against symptomatic disease may De less robust as
SARS-CoV-2 evolution continues from」N.1. Other formulations and/or platforms that
achieve roDbust neutralizing antibody responses adgainst currently circulatindg variants,
particularly 」N.1 descendent lineages, can also be considered.
In accordance with WHO SAGE policy, vaccination Drogrammes should continue to use
any Of the WHO emergency-use listed or Dredualified COVID-19 vaccines and
vaccination should not be delayed in anticipation of access to vaccines with an